Definium Therapeutics, Inc. 4

Chief Commercial Officer Matthew T. Wiley received an award of 62,500 Definium Therapeutics, Inc. common shares as a performance share unit vesting tranche.

On August 12, 2026, Definium Therapeutics, Inc. Chief Commercial Officer Matthew T. Wiley acquired 62,500 common shares at a stated price of $0.00 per share, representing the second tranche of performance share units originally granted on March 17, 2025. These shares are still subject to vesting conditions tied to Wiley’s continued employment through March 17, 2028 and to the achievement of specified clinical and regulatory milestones. Following this award, Wiley’s direct beneficial ownership increased to 237,133 common shares, with the overall value of both the new grant and his total holdings not precisely determinable from the filing due to the absence of a prevailing market price in the document.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-345836

Alert Tier

5